Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.09.2022 | Case report

Dabrafenib/trametinib

Macrophage activation syndrome: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Demarez B, et al. Macrophage activation syndrome associated with BRAF and MEK inhibitors during adjuvant treatment of melanoma. Journal of the European Academy of Dermatology and Venereology 36: e688-e689, No. 9, Sep 2022. Available from: URL: http://doi.org/10.1111/jdv.18130 Demarez B, et al. Macrophage activation syndrome associated with BRAF and MEK inhibitors during adjuvant treatment of melanoma. Journal of the European Academy of Dermatology and Venereology 36: e688-e689, No. 9, Sep 2022. Available from: URL: http://​doi.​org/​10.​1111/​jdv.​18130
Metadaten
Titel
Dabrafenib/trametinib
Macrophage activation syndrome: case report
Publikationsdatum
01.09.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-23532-0

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Ibuprofen

Case report

Tozinameran

Case report

Multiple drugs

Case report

Romiplostim